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o.co.in (T. SatyanAbstract Although a number of methods are available for evaluating Linezolid and its possible
impurities, a common method for separation if its potential impurities, degradants and enantiomer in a
single method with good efﬁciency remain unavailable. With the objective of developing an advanced
method with shorter runtimes, a simple, precise, accurate stability-indicating LC method was developed
for the determination of purity of Linezolid drug substance and drug products in bulk samples and
pharmaceutical dosage forms in the presence of its impurities and degradation products. This method is
capable of separating all the related substances of Linezolid along with the chiral impurity. This method
can also be used for the estimation of assay of Linezolid in drug substance as well as in drug product. The
method was developed using Chiralpak IA (250 mm 4.6 mm, 5 mm) column. A mixture of acetonitrile,
ethanol, n-butyl amine and triﬂuoro acetic acid in 96:4:0.10:0.16 (v/v/v/v) ratio was used as a mobile
phase. The eluted compounds were monitored at 254 nm. Linezolid was subjected to the stress conditions
of oxidative, acid, base, hydrolytic, thermal and photolytic degradation. The degradation products were
well resolved from main peak and its impurities, proving the stability-indicating power of the method.
The developed method was validated as per International Conference on Harmonization (ICH) guidelines
with respect to speciﬁcity, limit of detection, limit of quantiﬁcation, precision, linearity, accuracy,
robustness and system suitability.
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arayana Raju).1. Introduction
Linezolid (Zyvox), (S)-N-((3-(3-ﬂuoro-4-morpholinophenyl)-2-
oxooxazolidin-5-yl) methyl) acetamide, is a synthetic antibiotic
belonging to a new class of antimicrobials called the oxazolidi-
nones [1]. Linezolid is effective for the treatment of nosocomial
infections involving gram positive bacteria. The oxazolidinones
possess a unique mechanism of bacterial protein synthesis
inhibition [2]. Linezolid acts by inhibiting the initiation of
bacterial protein synthesis, a mechanism of action distinct from
that of any other antibiotics that are commercially available.
Linezolid was launched in May 2000 for the treatment of
patients with infections caused by gram-positive bacteria [3].
Linezolid
Imp-A
Imp-B
Imp-C
Imp-D
Separation of enantiomer and potential impurities of Linezolid using polar organic mode 273The daily dosage of Linezolid is 1200 mg/day. As per the ICH
guidelines all the impurities (known and unknown) have to be
controlled below 0.08% in drug substance w.r.t. Linezolid.
In the literature a number of methods have been described
for the determination of Linezolid and its impurities employing
various techniques such as HPLC [4–11], chiral HPLC [12–14],
capillary electrophoresis [15–18] and NMR [19]. The major
objective of the present work is to develop a single method for
the separation of chiral and nonchiral impurities of Linezolid in
drug substance and drug product and also the method should
have low LOD and LOQ values. The same method was used
for the estimation of assay of the drug substance and drug
product. Further the use of immobilized chiral HPLC column
ensures the column life unlike glycoprotein-based columns. So
far to our knowledge, no HPLC method has been reported for
simultaneous quantitative determination of the chiral impurity
and related substances in bulk drug and formulation of Line-
zolid. Therefore, in prevision of a racemic switch, it would be
useful and imperative to develop a simple and suitable method
for the measurement of Linezolid and related substances
including its enantiomer in bulk drug and formulations.
Hence a reproducible stability-indicating HPLC method
was developed for the quantitative determination of Linezolid
and its six impurities, namely Imp-A, Imp-B, Imp-C, Imp-D,
Imp-E and Imp-F (Fig. 1). This method was successfully
validated according to the International Conference Harmo-
nization (ICH) guidelines (Validation of Analytical Proce-
dures: Test and Methodology Q2).Imp-E
Imp-F
Figure 1 Structures of Linezolid and its six impurities.2. Experimental
2.1. Materials and reagents
Active pharmaceutical ingredient standards and samples were
supplied by Dr. Reddy’s Laboratories Limited, IPDO, Hyder-
abad, India. Commercially available Zyvox tablets from
Novartis Pharmaceuticals Corporation, USA, were used for
the dosage form analysis. The HPLC grade acetonitrile and
analytical grade triﬂuoro acetic acid and ethanol were pur-
chased from Merck, Darmstadt, Germany. N-butyl amine was
purchased from Spectrochem, Mumbai, India.
2.2. Equipment
The Waters HPLC system (Waters, Milford, USA) used consists
of a pump, auto sampler and a PDA detector. The output signal
was monitored and processed using empower-2 software. Cintex
digital water bath was used for hydrolysis studies. Photo stability
studies were carried out in a photo stability chamber (Sanyo,
Leicestershire, UK). Thermal stability studies were performed in
a dry air oven (Cintex, Mumbai, India).
2.3. Chromatographic conditions
The chromatographic separation was achieved on Chiralpak-IA
(250 mm 4.6 mm, 5 mm) column using a mobile phase con-
taining acetonitrile–ethanol–n-butylamine–triﬂuoro acetic acid
(96:4:0.10:0.16, v/v/v/v). The mobile phase was ﬁltered through
a nylon membrane (pore size 0.45 mm) ﬁlter. The ﬂow rate of the
mobile phase was 0.8 mL/min. The column temperature wasmaintained at 40 1C and the wavelength was monitored at
254 nm. The injection volume was 5 mL. A mixture of acetonitrile
and ethanol in the ratio of 96:4 (v/v) was used as diluent during
the standard and test samples preparation.
2.4. LC-MS/MS conditions
LC-MS/MS system (Agilent 1200 series liquid chromatograph
coupled with Applied Biosystem 4000 Q Trap quadrupole
mass spectrometer with analyst 1.4 software, MDS SCIEX,
USA) was used for the identiﬁcation of unknown compounds
formed during forced degradation studies. Chiralpak-IA
(250 mm 4.6 mm, 5 mm) column was used as stationary
phase. Acetonitrile–ethanol–n-butylamine–triﬂuoro acetic acid
(96:4:0.10:0.16, v/v/v/v) was used as mobile phase. The ﬂow
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tained at 40 1C. The analysis was performed in positive electro
spray ionization mode. Ion source voltage was 5500 V. Source
temperature was 450 1C. GSI and GS2 are optimized to 30
and 35 psi respectively. Curtain gas ﬂow was 20 psi.
2.5. Preparation of stock solutions
A stock solution of Linezolid (1.0 mg/mL) was prepared by
dissolving appropriate amount of drug in diluent. Working
solutions of 500 and 100 mg/mL were prepared from the above
stock solution for the related substance determination and
assay determination respectively. A stock solution of impu-
rities (mixture of Imp-A, Imp-B, Imp-C, Imp-D, Imp-E and
Imp-F) at 50 mg/mL was prepared in diluent.
2.6. Preparation of sample solution
To prepare the sample stock solution, twenty (n¼10) tablets of
Zyvox, each containing 600 mg of Linezolid, were accurately
weighed and crushed to a ﬁne powder. An appropriated amount
was transferred into an individual 100 mL volumetric ﬂask,
diluted to volume with diluent and sonicated for 10 mins.,
obtaining the ﬁnal concentration of 2 mg/mL of the active
pharmaceutical ingredient. 25 mL of this solution was diluted
to 100 mL with diluent to give a solution containing 500 mg/mL.
20 ml of this solution was diluted to 100 mL with diluent to give
a solution containing 100 mg/mL. These solutions were ﬁltered
through a 0.22-mm Nylon membrane ﬁlter.
2.7. Stress studies
Speciﬁcity is the ability of the method to measure the analyte
response in the presence of its potential impurities [20]. The
speciﬁcity of the developed LC method for Linezolid was
carried out in the presence of its six impurities. Stress studies
were performed at an initial concentration 500 mg/mL of
Linezolid on tablets to provide an indication of the stability
indicating property and speciﬁcity of the proposed method.
Intentional degradation was attempted to stress conditions of
UV light (254 nm), heat (70 1C), acid (2 M HCl at 70 1C), base
(0.01 M NaOH at 25 1C), hydrolytic (70 1C) and oxidation
(6.0% H2O2 at 25 1C) to evaluate the ability of the proposed
method to separate Linezolid from its degradation products.
For heat, light studies, study period was 10 days whereas for
hydrolysis and oxidative degradation study it was found to be
about 48 h. For base and acid degradation, the study period
was 2½ and 3½ h respectively. Peak purity test was carried out
for Linezolid peak by using PDA detector in stress samples.
Assay of stressed samples was performed (at 100 mg/mL) by
comparison with qualiﬁed reference standard and the mass
balance (% assayþ% impuritiesþ% degradation products)
for stressed samples was calculated. Assay was also calculated
for Linezolid sample by spiking all six impurities at the
speciﬁcation level (i.e. 0.08%).3. Method validation
The method has been validated for assay and related sub-
stances by HPLC as per ICH guidelines [21].3.1. Precision
The precision of the method was veriﬁed by repeatability and
by intermediate precision. Repeatability of the related-sub-
stance method was checked by (Waters HPLC system with
PDA detector, Milford, USA) injecting six individual pre-
parations of Linezolid real sample (600 mg tablets) spiked with
0.08% of its six impurities (0.08% of impurities with respect to
500 mg/mL Linezolid). The RSD of peak area for each
impurity was calculated. The intermediate precision of the
method was also evaluated using different analysts, different
instruments and different columns and performing the analysis
on three different days.
Assay method precision was evaluated by carrying out six
independent assays of real sample of Linezolid at 100 mg/mL level
against qualiﬁed reference standard. The intermediate precision of
the assay method was evaluated by different analysts.
3.2. Limit of detection (LOD) and quantiﬁcation (LOQ)
The LOD and LOQ for Linezolid and its impurities were
determined at a signal-to-noise ratio of 3:1 and 10:1, respec-
tively, by injecting a series of dilute solutions with known
concentrations. Precision study was also carried out at the
LOQ level by injecting six (n¼6) individual preparations and
calculating the RSD of the area.
3.3. Accuracy
The accuracy of the assay method was evaluated in triplicate
(n¼3) at the three concentration levels of 50, 100 and 150 mg/mL
(50%, 100% and 150%) of drug product, and the recovery was
calculated for each added (externally spiked) concentration.
For all impurities, the recovery was determined in triplicate
for 50%, 100% and 150% (i.e., 0.20, 0.40 and 0.60 mg/mL
respectively) of the analyte concentration (500 mg/mL) of the
drug product, and the recovery of the impurities was calculated.
3.4. Linearity
Linearity test solutions for the assay method were prepared
from Linezolid stock solutions at ﬁve concentration levels from
50% to 150% of assay analyte concentration (50, 75, 100, 125
and 150 mg/mL). The peak area versus concentration data was
treated by least-squares linear regression analysis. Linearity
test solutions for the related substance method were prepared
by diluting stock solutions to the required concentrations. The
solutions were prepared at seven concentration levels from
LOQ to 150% of the speciﬁcation level (LOQ, 0.04, 0.06, 0.08,
0.10, 0.12 and 0.16%) with respect to the normal sample
concentration (500 mg/mL). The correlation coefﬁcients, slopes
and Y-intercepts of the calibration curve were determined.
3.5. Robustness
The robustness of an analytical procedure is a measure of its
capability to remain unaltered by small, but deliberate varia-
tions in method parameters and provides an indication of its
reliability during normal usage.
To determine the robustness of the method the experimen-
tal conditions were deliberately changed. The resolution of
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Linezolid were evaluated. The mobile phase ﬂow rate was
0.8 mL/min; to study the effect of ﬂow rate on resolution it
was changed to 0.64 and 0.96 mL/min. The effect of column
temperature on resolution was studied at 35 1C and 45 1C
(instead of 40 1C). The effect of the percent organic strength
on resolution was studied by varying ethanol by 10% to
þ10% from the initial composition.
3.6. Stability of solution and mobile phase
The stability of Linezolid in solution was determined by
leaving test solutions of the sample and reference standard in
tightly capped volumetric ﬂasks at room temperature for 48 h
during which they were assayed at 12 h intervals. Stability of
mobile phase was determined by analysis of freshly prepared
sample solutions at 12 h intervals for 48 h and comparing the
results with those obtained from freshly prepared reference
standard solutions. The mobile phase was prepared at the
beginning of the study period and not changed during the
experiment. The % assay of the results was calculated for both
the mobile phase and solution-stability experiments.
The stability of Linezolid and its impurities in solution for
the related substance method was determined by leavingFigure 2 Linezolid spi
Table 1 LOD, LOQ, regression and precision data.
Parameter Linezolid Imp-A Imp-
LOQ (mg/mL) 0.120 0.085
LOD (mg/mL) 0.035 0.025
0.5
Regression equation (y)
Slope (b) 40897 35011 3809
Intercept (a) 350.12 7.03 4
Correlation coefﬁcient 0.9996 0.9998
Y-intercept at 100% level 2.1% 0.1% 
R square value 0.9995 0.9996
Precision (%RSD) 2.1 2.9
Intermediate precision (%RSD)a 2.3 2.2
Linearity range is LOQ-200% with respect to 500 mg/mL Linezolid for i
Linezolid for assay.
aSix determinations using LOQ solution for impurities and 100 mg/mspiked sample solution in a tightly capped volumetric ﬂask
at room temperature for 48 h and measuring the amounts of
the eleven impurities at every 12 h. The stability of mobile
phase was also determined by analysis freshly prepared
solution of Linezolid and its impurities at 12 h intervals for
48 h. The mobile phase was not changed during the study
period.4. Results and discussion
4.1. Method development and optimization
The main objective while developing this method was to have
a single method for separation of impurities A,B, C, E and F
along with the separation of enantiomer of Linezolid (impur-
ity-D) from Linezolid. As the separation demands the resolu-
tion of chiral and non-chiral impurities together, chiral
stationary phases based on carbohydrate like cellulose and
amylose were chosen as ﬁrst choice. Initially the separation
was attempted in both normal phase and reverse phase. None
of the normal phase and reverse phase-based chiral columns
was able to separate all the impurities. Furthur trials have
been carried out using a mixture of polar organic solventsked chromatogram.
B Imp-C Imp-D Imp-E Imp-F
0.080 0.095 0.075 0.120 0.130
0.025 0.030 0.025 0.035 0.040
4 33697 38450 40624 41462
6.40 30.13 126.50 376.79 57.55
0.9998 0.9998 0.9999 0.9997 0.9998
0.3% 0.2% 0.8% 2.3% 0.3%
0.9997 0.9997 0.9998 0.9994 0.9996
1.6 2.0 1.7 2.2 2.3
2.1 2.4 2.3 1.6 2.7
mpurities; Linearity range is 50–150% with respect to 100 mg/mL of
L for assay of Linezolid.
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amine. No sign of separation between the enantiomers have
seen in Chiral pak-IB and Chiral pak-IC columns. Chiral pak-IA
column was found to be showing excellent separation of all
the impurities using acetonitrile and ethanol along with the
combination of triﬂuoro acetic acid and n-butyl amine in
mobile phase. The mobile phase composition was ﬁxed as
acetonitrile, ethanol, triﬂuoro acetic acid and n-Butyl amine in
96:4:0.16:0.10 (v/v/v/v) ratio with an isocratic elution. TheFigure 3 Complete degradation proﬁle of Linezolid along with the %ﬂow rate of the mobile phase was ﬁxed as 0.8 mL/min. A
mixture of acetonitrile and ethanol in the ratio of 96:4(v/v)
was chosen as the diluent, as the blank chromatogram was
clean without any interference with analyte peak and the
impurity peaks. Also no interference from the excipients was
observed. Under optimized conditions Linezolid and its six
impurities were well separated with resolution greater than 2.5;
typical retention times were approximately 14.20, 4.53, 5.23,
6.60, 7.29, 12.66, 15.58 min for Linezolid, impurity-A,impurity formation and corresponding mass nos. of impurities.
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F, respectively. System suitability parameters were evaluated
for Linezolid and its six impurities. Tailing factor for all six
impurities and Linezolid was found to be less than 1.2
4.2. Validation of the method
4.2.1. Precision
The RSD of assay of Linezolid during the assay method
repeatability study was 1.3% and the RSD for the area of Imp-
A, Imp-B, Imp-C, Imp-D, Imp-E and Imp-F in related
substance method repeatability study was within 6.6%. The
RSD of the assay results obtained in the intermediate precision
study was within 1.2% and the RSDs for the area of Imp-A,
Imp-B, Imp-C, Imp-D, Imp-E and Imp-F were well within
3.80%, conforming good precision of the method. These
results conﬁrmed that the method was highly precise (Fig. 2).
4.2.2. Limits of detection and quantiﬁcation
The limit of detection, limit of quantiﬁcation and precision at
LOQ values for Linezolid and its six impurities are shown in
Table 1.
4.2.3. Accuracy
Recovery of Linezolid from pharmaceutical dosage forms
ranged from 96.4% to 99.6%. Recovery of the six impurities
from pharmaceutical dosage forms ranged from 96.9% to
103.2%.
4.2.4. Linearity
The linearity calibration plot for the assay method was
obtained over the calibration ranges tested, i.e. 50–150 mg/
mL and correlation coefﬁcient obtained was greater than
0.999. The result shows that an excellent correlation existed
between the peak area and concentration of the analyte.
Linear calibration plot for the related substance method
was obtained over the calibration ranges tested, i.e. LOQ to
0.30% for impurities. The correlation coefﬁcient obtained was
greater than 0.999. The above result shows that an excellent
correlation existed between the peak area and the concentra-
tion of Imp-A, Imp-B, Imp-C, Imp-D, Imp-E and Imp-F.
4.2.5. Robustness
In all the deliberate varied chromatographic conditions (ﬂow
rate, column temperature and composition of organic solvent),
all analytes were adequately resolved and elution orders
remained unchanged. The resolution between critical pairs
was greater than 2.0 and tailing factor for Linezolid and its
impurities was less than 1.2. The assay variability of Linezolid
was within 71%. The variability in the estimation of Line-
zolid impurities was within 78%.
4.2.6. Stability in solution and in the mobile phase
RSD (%) for assay of Linezolid during solution stability and
mobile phase stability experiments was within 1.2%. No
signiﬁcant changes in the amounts of the six impurities were
observed during solution stability and mobile phase stability
experiments when performed using the related substances
method. The results from solution stability and mobile phase
stability experiments conﬁrmed that standard solutions andsolutions in the mobile phase were stable for up to 48 h during
assay and determination of the related substances.
4.2.7. Results from forced degradation studies
All the results of forced degradation studies are mentioned in
Fig. 3. Assay studies were carried out for stress samples (at
100 mg/mL) against qualiﬁed Linezolid reference standard.
The mass balance (% assayþ% sum of all compoundsþ %
sum of all degradants) results were calculated for all stressed
samples and found to be more than 99.4%. The purity and
assay of Linezolid was unaffected by the presence of its
impurities and degradation products, thereby conﬁrming the
stability-indicating power of the developed method.5. Conclusion
The simple isocratic LC method developed for quantitative
analysis of Linezolid and the related substances in bulk
samples and pharmaceutical dosage forms is precise, accurate,
linear, robust and speciﬁc. Satisfactory results were obtained
from validation of the method. The method is stability-
indicating and can be used for routine analysis of production
samples and to check the stability of samples of Linezolid in
bulk drugs and in pharmaceutical dosage forms.
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